Background: Tranexamic acid (TXA) is an antifibrinolytic that is regularly used to reduce bleeding in surgical specialties.

Objectives: To assess the effects of subcutaneous TXA in oculofacial plastic surgeries, with the hypothesis that TXA reduces postoperative ecchymosis and edema.

Methods: A prospective, randomized, double-blind, split-face study. The sides of the face were randomized to local anesthetic (bupivacaine with epinephrine) mixed with TXA or sodium chloride (placebo). Photographs were taken immediately post-operatively and on post-operative day 7. Photographs were graded by two masked investigators using the Surgeon Periorbital Rating of Edema and Ecchymosis criteria. Patients selected the side that they subjectively determined to have less ecchymosis and edema. As a secondary outcome, patients rated pain on each side of their face using the Wong-Baker FACES pain scale.

Results: Twenty-four patients undergoing bilateral, symmetric oculofacial surgery were included in the study. There was a statistically significant difference in postoperative periocular ecchymosis on POD7 (with TXA 0.91 ± 0.73 versus placebo 1.61 ± 1.03; p = 0.020) and in periocular edema on POD1 (with TXA 1.30 ± 0.76 versus placebo 2.00 ± 0.85; p = 0.028). All patients selected the side of the face receiving TXA as having less periocular ecchymosis and edema. There was no statistically significant difference in subjective pain level between the side receiving TXA versus placebo. There were no intraoperative or postoperative complications.

Conclusions: Subcutaneous TXA was safe and reduced periocular ecchymosis and edema compared to contralateral placebo injections in this series of patients undergoing bilateral oculofacial plastic surgeries.

Download full-text PDF

Source
http://dx.doi.org/10.1093/asj/sjaf036DOI Listing

Publication Analysis

Top Keywords

ecchymosis edema
16
periocular ecchymosis
12
versus placebo
12
txa
9
tranexamic acid
8
oculofacial surgery
8
prospective randomized
8
subcutaneous txa
8
oculofacial plastic
8
plastic surgeries
8

Similar Publications

Background: Tranexamic acid (TXA) is an antifibrinolytic that is regularly used to reduce bleeding in surgical specialties.

Objectives: To assess the effects of subcutaneous TXA in oculofacial plastic surgeries, with the hypothesis that TXA reduces postoperative ecchymosis and edema.

Methods: A prospective, randomized, double-blind, split-face study.

View Article and Find Full Text PDF

Existing data on tranexamic acid (TXA) in rhinoplasty are mixed. Compare blood loss, edema, and bruising in patients undergoing septorhinoplasty with or without intravenous (IV) TXA, measured by estimated blood loss and photograph review of edema/ecchymosis. Randomized controlled trial (NCT05774717).

View Article and Find Full Text PDF

Background: Tranexamic acid (TXA) is an antifibrinolytic agent with promising benefits in facial rejuvenation surgery. The best way to administer this medication for therapeutic value is currently unknown. This study compared outcomes for facelift patients given TXA intravenously versus locally in tumescent solution.

View Article and Find Full Text PDF

To compare postoperative edema, ecchymosis, and pain after rhinoplasty using conventional (classical) osteotomy versus powered (electric) micro-saw osteotomy techniques. Between December 2021 and May 2023, 90 patients aged 18 to 45 underwent rhinoplasty at our clinic. Of these, 45 patients underwent lateral and transverse osteotomy with powered saw instruments, whereas 45 underwent conventional osteotomy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!